Trastuzumab should remain as standard of care for HER2-positive breast cancer

[News]

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that...

More... (http://www.medicalnewstoday.com/releases/283247.php)